Focus Sectors | Verticals
MedTech
MedTech is where Switzerland’s deep heritage in precision engineering, microtechnology, and life sciences converges to solve critical healthcare challenges. This vertical is focused on tangible medical devices for surgery, patient monitoring, advanced diagnostics, and clinical support, integrating disciplines like robotics and AI to improve patient outcomes.
For this reason, “MedTech is Switzerland’s natural playground”. The ecosystem’s single greatest advantage is its “tight loop between engineers, clinicians, and regulators”, which allows startups to de-risk innovation and iterate solutions at a speed rarely seen elsewhere. With over 150 VC-backed startups and $1.4B in funding since 2019, the sector successfully integrates multiple disciplines to build value-based business models that are ready for global markets.
This page provides a detailed look at this powerhouse sector. Explore the key statistics, discover the “companies to watch” in fields from telerobotics to AI-powered diagnostics, and learn how Swiss MedTech teams are building the future of healthcare.
Notable Companies in MedTech
Key Stats*
150+
VC-Backed startups
$1.4B
VC funding since 2019
$6.1B
Combined Enterprise Value
Tob Hubs in Zurich, Lausanne (EPFL) and Geneva.
* All data is taken from the Swiss Deep Tech Report 2025.
Companies to watch
Cell line technology for gene therapy.
Immune system rejuvenation.
Modular AI solutions accelerating drug discovery.
AI fingerprinting technology for molecular identification.
Genomic data.
Protein engineering.
Platform for cell and gene therapy manufacturing at scale.
RNA sequencing at scale.
The AI-first lab for protein design.
«The Swiss ecosystem gives Medtech teams the freedom to build, test, and scale ideas quickly. We see a tight loop between engineers, clinicians and regulators that lets us de-risk innovation fast. Once we prove a product here, we turn to the US for the deep capital, market scale and strategic partnerships that drive full commercial rollout and the path to public listing. By keeping robotics simple, surgeon-controlled, and cost-aligned, we can make advanced care a routine option for every hospital.»
Michael Friedrich
COO
Distalmotion
«Medtech is Switzerland’s natural playground. The depth of life science, shaped by Roche, Novartis, and a network of top universities, meets precision engineering, robotics, and increasingly Al. Integrating these dissimilar disciplines successfully is the key to innovation. Novel solutions allow to diagnose more accurately, treat more effectively, and build value based business models. It is at these crossroads of science and engineering where Zühlke Ventures keeps placing its bets.»
Patrick Griss
CEO Ventures & Partner
Zühlke
Who’s Who in MedTech
-
>>venture>>
Zurich
>>venture>> is Switzlerland’s leading early-stage startup competition. Established in 1997, it is co-organized by ETH Zurich, McKinsey & Company, Knecht Holding, Innosuisse, and EPFL. Every year, the competition supports innovative startups by providing them with over CHF 590,000 in non-dilutive funding, mentorship and access to an vast network of industry experts.
-
-
Bio-Technopark Schlieren-Zürich
Zurich
The Bio-Technopark is a life science park housing 60 companies and organizations, as well as 80 academic research groups. The park has offices and laboratories.
-
-
Boldbrain Startup Challenge
Lugano
Boldbrain Startup Challenge is an accelerator designed for early-stage startups and entrepreneurs with innovative ideas, ready to launch and develop their business from Canton Ticino.
-
-
Eawag: Swiss Federal Institute of Aquatic Science and Technology
Duebendorf
Eawag is one of the world’s leading aquatic research institutes.
-
EPFL Innovation Park
Lausanne
EPFL Innovation Park: A hive of interaction between academia and business, attracting outstanding, innovative projects and empowering them to flourish, scale up and transform society.
Most Active Swiss VCs in MedTech
-
4FOx Ventures
Focus on early stage
Medtech
-
Alpana
Focus on early stage
ICT
-
BioMedPartners
Focus on early stage
Biotech
Participated in funding round of >100 mio.
-
Business Angels Switzerland
Focus on early stage
ICT
-
Kickfund
Focus on early stage
Climate Tech & Energy
-
Lakestar
All stages
ICT
Participated in funding round of >100 mio.
Invested in Unicorn
-
Occident
Focus on early growth
Medtech
Participated in funding round of >100 mio.
-
Redalpine Ventures
All stages
Biotech
Participated in funding round of >100 mio.
Invested in Unicorn
-
SICTIC
Focus on early stage
ICT
-
Spicehaus Partners
Focus on early stage
ICT
Data-based insights research
Unmatched Translational Infrastructure
Medical technology has deeper roots in Switzerland than perhaps any other deep tech vertical. The country hosts the highest density of medtech companies per capita in Europe, with around 1,400 firms employing 71’700 employees and generating CHF 23.4 billion in revenue in 2023 – growing at twice the rate of Swiss GDP, according to the Swiss Medtech Sector Study 2024 by Swiss Medtech and the Helbling Group. That growth is not incidental: Swiss medtech companies reinvest 12% of their turnover into R&D, well above European sector averages, and medtech has become the single largest category of Swiss patent filings at the European Patent Office, outpacing both pharma and biotech. Switzerland already leads the world in patents per capita; medtech is the primary reason why.
What sets Switzerland apart is a national network of translational centres built specifically to bridge the lab-to-clinic gap. The largest is Wyss Zurich, launched in 2015 with a USD 120 million endowment from philanthropist Hansjörg Wyss – the ETH alumnus who sold orthopedic company Synthes to Johnson & Johnson for USD 21 billion in 2011 and directed the proceeds back into Swiss research infrastructure. Embedded within ETH Zurich and the University of Zurich, Wyss Zurich focuses on regenerative medicine, robotics and medical devices. In Geneva, the Wyss Center for Bio and Neuroengineering has produced more than 8 spin-offs and spin-ins targeting neurological and psychiatric disorders. In Bern, sitem-insel sits directly on the Inselspital campus, co-locating clinical care, research, regulation and entrepreneurship and incubating more than 25 startups to date. Together these 3 national nodes give Swiss medtech founders direct access to GMP manufacturing facilities, regulatory pathways and clinical validation partners that would take years to assemble independently elsewhere in Europe.
A Deep and Growing Startup Ecosystem
Switzerland is home to more than 150 VC-backed medtech startups, with the sector raising USD 1.4 billion between 2019 and 2024, a 410% increase over that 5-year period, according to the Swiss Deep Tech Report 2025. The most recent annual data from the Swiss Venture Capital Report 2026 confirms that medtech investment held stable even as Swiss venture capital as a whole rebounded 24% to CHF 2.95 billion – with Distalmotion’s CHF 120.8 million Series G the third-largest round in the country that year across all sectors. The EY Swiss Startup Barometer 2025 recorded CHF 275 million deployed into medtech across 51 deals in 2024, and notes the health sector as a whole has held the largest share of Swiss startup financing for 2 consecutive years.
The ecosystem spans a wide range of sub-disciplines. Surgical robotics has produced the most visible flagship: Distalmotion, an EPFL spin-off based in Lausanne, has treated nearly 3,000 patients in Europe and the US with its Dexter robot, secured FDA authorization across 3 indications, and raised USD 150 million in its Series G round in late 2025. Neurotech, AI diagnostics and orthopedics are equally well represented, with the TOP 100 Swiss Startup Award 2025 listing 12 medtech companies in its ranking, including 1 in the top 10, selected by a jury of 100 leading investors. Significant startup clusters operate simultaneously in Zurich, Lausanne, Geneva, Basel and Bern, each supported by its own translational centre and university hospital, ensuring that no single city concentrates the sector’s talent or capital.
Corporate Acquisition Flywheel
This flywheel is producing measurable outcomes. In July 2024, Basel-based Straumann Group completed the full acquisition of Mininavident, a 2013 spin-out from the University Hospital Basel and FHNW that developed the DENACAM system, the world’s first miniaturized dynamic navigation system for dental implants. Straumann first took a 39% stake in 2021 and co-developed the product under the Straumann Falcon brand before buying out the remaining shareholders 3 years later. In October 2024, EssilorLuxottica acquired Bern-based Ikerian AG, operating under the RetinAI brand and based at sitem-insel, whose FDA-cleared and CE-marked platform uses AI to process retinal images for diagnosing age-related macular degeneration, diabetic retinopathy and glaucoma; the company had raised USD 6.18 million in Series A funding before the exit.
Ypsomed, for its part, has run its own startup competition for more than 15 years, a program that recognised CasCination before it became a global standard in navigated surgery. These 3 examples follow a repeating pattern: a Swiss startup solves a clinical problem, validates in Swiss hospitals, attracts a strategic investment from a Swiss corporate, and is ultimately acquired – giving founders faster paths to exit and investors predictable liquidity timelines that are comparatively rare in the broader European medtech landscape.
Success Stories
-
Read more: 20 Reforms to Compete Globally: The Swiss Startup Agenda by SSASwitzerland’s startup ecosystem has reached a critical inflection point. While the country continues to lead Europe in per-capita spinout creation and deep tech innovation, structural…
-
Read more: A Surprising Record Sparks OptimismOn 3 February, the Venture Capital Report was published, analysing investments in Swiss start-ups in 2025. Despite growth of 24 per cent, the total capital…
-
Read more: Switzerland: A Leading Global Scale-up Hub
More money has flowed into all Swiss scale-ups per capita than into scale-ups in the US or Israel. This is backed by a ten-year growth…
MedTech
News
-
Neurosoft Bioelectronics Closes $7.5M Oversubscribed Seed Round
Neurosoft Bioelectronics, a Swiss neurotechnology startup developing scalable and soft brain-computer interfaces (BCIs), today announced that it has raised a $7.5 million oversubscribed seed financing…
startupticker.ch
-
Medtech scale-up vVARDIS achieves unicorn status
vVARDIS Holding AG, a Zug-based dental medtech company pioneering non-invasive cavity treatment, attracted a strategic minority investment from Apollo-managed funds. The investment establishes vVARDIS as…
startupticker.ch
-
ONWARD Medical raises over EUR 40 Million in capital increase
ONWARD Medical successfully raised an amount of EUR 40.6M in gross proceeds by way of an accelerated bookbuild offering through a private placement with institutional…
startupticker.ch
-
Rivia raises $15M Series A to bring clinical trials into the agentic AI era
Rivia’s data engine unifies clinical trial data, applies scientific logic at scale, and embeds AI agents directly into review workflows to reduce trial costs by…
startupticker.ch
-
USD 50 million to advance Polares Medical U.S. expansion
Polares Medical SA, a Lausanne headquartered clinical-stage structural heart company developing the MRace Posterior Leaflet Replacement (PLR) system for mitral regurgitation (MR), today announced the…
startupticker.ch
-
Oversubscribed $7M Series A to boost Xsensio biosensing clinical deployment
Xsensio SA, a Swiss deep-tech company pioneering near real-time continuous biochemical monitoring, today announced the successful closing of a $7M oversubscribed Series A financing round. The…
startupticker.ch
FAQ on MedTech
1. Why is MedTech considered Switzerland’s “natural playground”?
The sector perfectly combines the country’s historic strengths: deep life science expertise, precision engineering, robotics, and, increasingly, AI.
2. What is the total VC funding for MedTech in Switzerland?
The Swiss MedTech sector has raised $1.4 billion between 2019 and 2024, with funding growing 410% in that period. 2024 was its most active funding year on record.
3. How does the Swiss ecosystem benefit MedTech startups?
The “tight loop between engineers, clinicians, and regulators” allows startups to “de-risk innovation fast”. This rapid, collaborative iteration is a key advantage for building complex medical devices.
4. Which are the leading Swiss MedTech companies in surgical robotics?
The sector is anchored by major scale-ups like Distalmotion, which is commercializing its surgical robot, and rising stars like nanoflex (telerobotics) and LEM surgical.
5. What are the key investment trends in Swiss medical device startups?
Key trends include AI-powered diagnostics (scanvio), advanced surgical robotics (Distalmotion), telerobotics (nanoflex), and novel therapeutic devices (hilo, ArgaMedtech).
